Protein-protein interactions (PPIs) are involved in almost every cellular process. They represent attractive targets for modulating signaling pathways leading to disease states. However, they are challenging to target with small molecules, peptides for example, due to varied reasons. Although a growing number of PPIs have become validated drug targets, there is only a little percentage that have been used to successfully design potent drugs.

PPIs play an important role in signaling events leading to inflammation. Many inflammatory diseases are based on specific signaling pathways inside the cells which are in turn driven by a prior event of a protein-protein interaction or several protein-protein interactions.

It has been clearly shown by many investigators across the world that targeting such interactions would be the best way to attenuate the signaling events and eventually inflammation. In the last few years, various PPIs modulators have entered clinical studies, some of which have been approved for marketing, strengthening the idea that modulators targeting PPIs have broad prospects in clinical research.

The conventional methods using medicinal chemistry protocols are less effective and time-consuming for designing and identifying PPI modulators. Thus, it is necessary to develop more effective approaches for screening the PPI modulators. A wide variety of strategies including High-throughput screening (HTS), in-silico modeling, and the most recent Artificial Intelligence (AI), could multiply the results in terms of time and effort.

We would like to invite potential authors researching on topics associated with studies focused on the role of protein-protein interactions as well as targeting those in inflammatory signaling leading to multiple diseases including sepsis etc.

Articles specifically encompassing the following are welcome:

1) Artificial Intelligence (AI) in PPI-based drug discovery in immune-mediated inflammatory disease.
2) Novel cell-based high output assays for quicker screening of novel drugs against PPI's in immune-mediated inflammatory disease.
3) Novel PPI's and their therapeutic targeting in inflammation and sepsis.

Please note: Bioinformatics or Computational Analysis of public genome or transcriptome databases need to be accompanied by robust and relevant validation to be submitted to this section. Manuscripts describing the pharmacological action of drugs used in traditional medicine in models of disease are not in scope of this Research Topic, unless they have a strong focus on the immune system.

This Research Topic is the third volume of the “Community Series in Targeting Signalling Pathways in Inflammatory Diseases”. Please see the first volume here and the second volume here

Are you interested in contributing a manuscript to this Research Topic?

Community Series in targeting signalling pathways in inflammatory diseases - Volume III